Kyras Therapeutics is a biotech company
Kyras Therapeutics is a biotech company. According to data from the National Cancer Institute, more than 30 percent of all human cancers are driven by mutations in RAS genes, including 95% of pancreatic, 45% of colorectal, and 35% of lung cancers, among many others.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 11, 2015 | Series A | — | 1 | Versant Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Versant Ventures | Yes | Series A |